Understanding the authentic patient experience can redefine the success of your clinical trial before you design it

Understanding the authentic patient experience can redefine the success of your clinical trial before you design it

This month’s edition of PME features a number of articles and opinion pieces on diversity and inclusion in clinical trials. Our Director, Su Smith was interviewed as part of a featured article by Danny Buckland examining the changing tides in clinical trials. Danny highlights in the piece that though there are 1,518 COVID-19 studies registered on clinicaltrials.gov, less than 0.3% are collecting data on ethnicity. Su contributes our experience are Origins that there is a willingness within the Pharmaceutical Industry to change attitudes towards clinical trial populations – making them less about academic and clinical outcomes and more inclusive of patient experience and priorities. Origins contribute to this changing attitude by helping our pharmaceutical and medical clients to understand the authentic patient experience. This can help to design more patient-centric clinical trials where the trial participants are more representative of the true patient population (and not just the easiest to access), secondary outcomes are inclusive of patient priority and trial materials and communication are written using the lexicon of those that experience the condition and not academics that have defined it.

Elsewhere in the June edition of PME, Su share’s her thoughts on four key factors that Origins believe can decrease the burden of participating in a clinical trial to patients. The burden of participation is one of the key factors stated as a reason for drop out of a clinical trial and costs the pharmaceutical industry tens of thousands of dollars every year. This cost contributes to the already expensive process of developing and bringing a drug to market and may play a price in the cost of medications. If more can be done therefore to decrease the burden to patients participating in trials, this could decrease the cost burden to payers in future years.

Origins provide actionable patient insights that can re-define your success in clinical trials:

  • Learning the language that patients use to describe their symptoms and condition ensures that the right/most effective communications and materials are written
  • Understanding of life with the condition and symptoms experienced will help the planning of protocols (secondary endpoints etc) and logistics that will reduce the possibility of participant dropout – a great financial burden, as well as reducing the burden to patients of participating in the trial
  • Understanding what could have been improved post-trial, will ensure ongoing learnings are captured and applied

Check out this month’s edition of PME for more insights and information.